Literature DB >> 11459268

The surgical management of pancreatic neuroendocrine tumors.

K Azimuddin1, R S Chamberlain.   

Abstract

NETs of pancreas are rare and may or may not be associated with symptoms of hormone overproduction. Treatment is required for control of tumor growth and for relief of symptoms associated with excess hormone. With advances in the nonsurgical management of many hormone-related symptoms (e.g., proton pump inhibitors or somatostatin analogues), care for many of these patients has shifted toward the control of tumor progression. Complete surgical resection is the only curative treatment for these tumors. With improvements in the preoperative imaging and intraoperative localization techniques, it is hoped that these tumors will be identified and resected for cure with increased frequency. For patients with hepatic metastasis, initial expectant observation and medical management of symptoms is appropriate in view of the long and indolent course of the disease. Hepatic arterial embolization is the preferred mode of palliation for pain and hormonal symptoms. A curative hepatic resection may be possible in selected patients.

Entities:  

Mesh:

Year:  2001        PMID: 11459268     DOI: 10.1016/s0039-6109(05)70140-7

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  10 in total

1.  Surgical experiences of functioning neuroendocrine neoplasm of the pancreas.

Authors:  Chang Moo Kang; Se Ho Park; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

2.  Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.

Authors:  Xiang Da Dong; Brian I Carr
Journal:  Med Oncol       Date:  2010-11-24       Impact factor: 3.064

3.  Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.

Authors:  Walid Shaib; Kisha Mitchell; M Wasif Saif
Journal:  Yale J Biol Med       Date:  2010-03

4.  Neuroendocrine Tumors of the Pancreas.

Authors:  James M. McLoughlin; Joseph A. Kuhn; Jeffrey T. Lamont
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

5.  Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1.

Authors:  V Gutiérrez; M Cobo; D Olea; J García; C Ramírez; D Bautista; J Alcalde
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

Review 6.  Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.

Authors:  Peter Gunvén
Journal:  Med Oncol       Date:  2007-08-03       Impact factor: 3.064

7.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

8.  Surgical treatment of neuroendocrine liver metastases.

Authors:  Ser Yee Lee; Peng Chung Cheow; Jin Yao Teo; London L P J Ooi
Journal:  Int J Hepatol       Date:  2012-01-26

9.  Insulinoma.

Authors:  Andrew R Burns; Alan P B Dackiw
Journal:  Curr Treat Options Oncol       Date:  2003-08

10.  Insulinoma-Induced Hypoglycemia in a Patient with Insulinoma after Gastrojejunostomy for Prepyloric Ulcer.

Authors:  Yavuz Savas Koca; Bünyamin Aydın; Tugba Koca; Mustafa Tevfik Bülbül; Mehmet Numan Tamer
Journal:  Case Rep Surg       Date:  2015-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.